Antiphospholipid syndrome epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
Feham Tariq (talk | contribs) |
(→Race) |
||
| (9 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Antiphospholipid syndrome}} | {{Antiphospholipid syndrome}} | ||
{{CMG}}{{AE}}{{FT}} | {{CMG}}; {{AE}}{{FT}} | ||
==Overview== | ==Overview== | ||
The incidence of antiphospholipid syndrome (APS) is approximately 5 cases per 100,000 persons per year. The prevalence of APS is approximately 40-50 cases per 100,000 persons worldwide. APS due to [[systemic lupus erythematosus]] ([[SLE]]) is more commonly seen in the African American and Hispanic population. Middle aged women are more commonly affected by APS than males. | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
The epidemiology and demographics of antiphospholipid syndrome is as follows:<ref name="pmid28262233">{{cite journal| author=Cervera R| title=Antiphospholipid syndrome. | journal=Thromb Res | year= 2017 | volume= 151 Suppl 1 | issue= | pages= S43-S47 | pmid=28262233 | doi=10.1016/S0049-3848(17)30066-X | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28262233 }} </ref><ref name="pmid24461539">{{cite journal| author=Gómez-Puerta JA, Cervera R| title=Diagnosis and classification of the antiphospholipid syndrome. | journal=J Autoimmun | year= 2014 | volume= 48-49 | issue= | pages= 20-5 | pmid=24461539 | doi=10.1016/j.jaut.2014.01.006 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24461539 }} </ref><ref name="pmid18937631">{{cite journal| author=Lockshin MD| title=Update on antiphospholipid syndrome. | journal=Bull NYU Hosp Jt Dis | year= 2008 | volume= 66 | issue= 3 | pages= 195-7 | pmid=18937631 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18937631 }} </ref><ref name="Gómez-PuertaCervera2014">{{cite journal|last1=Gómez-Puerta|first1=Jose A.|last2=Cervera|first2=Ricard|title=Diagnosis and classification of the antiphospholipid syndrome|journal=Journal of Autoimmunity|volume=48-49|year=2014|pages=20–25|issn=08968411|doi=10.1016/j.jaut.2014.01.006}}</ref> | |||
===Incidence=== | ===Incidence=== | ||
*The incidence of antiphospholipid syndrome (APS) is approximately 5 cases per 100,000 persons per year. | *The incidence of antiphospholipid syndrome (APS) is approximately 5 cases per 100,000 persons per year. | ||
| Line 13: | Line 16: | ||
===Case-fatality rate/Mortality rate=== | ===Case-fatality rate/Mortality rate=== | ||
*The case-fatality rate/mortality rate of catastrophic APS is approximately 50%. | |||
*The case-fatality rate/mortality rate of | |||
===Age=== | ===Age=== | ||
| Line 21: | Line 23: | ||
===Race=== | ===Race=== | ||
*APS due to systemic lupus | *APS due to [[systemic lupus erythematosus]] ([[SLE]]) is more commonly seen in the African American and Hispanic population. | ||
===Gender=== | ===Gender=== | ||
| Line 27: | Line 29: | ||
===Region=== | ===Region=== | ||
*There is no particular regional predilection. | *There is no particular regional predilection. | ||
==References== | ==References== | ||
Latest revision as of 20:10, 24 April 2018
|
Antiphospholipid syndrome Microchapters |
|
Differentiating Antiphospholipid syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Antiphospholipid syndrome epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Antiphospholipid syndrome epidemiology and demographics |
|
FDA on Antiphospholipid syndrome epidemiology and demographics |
|
CDC on Antiphospholipid syndrome epidemiology and demographics |
|
Antiphospholipid syndrome epidemiology and demographics in the news |
|
Blogs on Antiphospholipid syndrome epidemiology and demographics |
|
Risk calculators and risk factors for Antiphospholipid syndrome epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Feham Tariq, MD [2]
Overview
The incidence of antiphospholipid syndrome (APS) is approximately 5 cases per 100,000 persons per year. The prevalence of APS is approximately 40-50 cases per 100,000 persons worldwide. APS due to systemic lupus erythematosus (SLE) is more commonly seen in the African American and Hispanic population. Middle aged women are more commonly affected by APS than males.
Epidemiology and Demographics
The epidemiology and demographics of antiphospholipid syndrome is as follows:[1][2][3][4]
Incidence
- The incidence of antiphospholipid syndrome (APS) is approximately 5 cases per 100,000 persons per year.
Prevalence
- The prevalence of APS is approximately 40-50 cases per 100,000 persons worldwide.
Case-fatality rate/Mortality rate
- The case-fatality rate/mortality rate of catastrophic APS is approximately 50%.
Age
- The commonly affected age groups are young to middle aged adolescents.
- However, APS is also seen in children and elderly age group.
Race
- APS due to systemic lupus erythematosus (SLE) is more commonly seen in the African American and Hispanic population.
Gender
- Middle aged women are more commonly affected by APS than males.
Region
- There is no particular regional predilection.
References
- ↑ Cervera R (2017). "Antiphospholipid syndrome". Thromb Res. 151 Suppl 1: S43–S47. doi:10.1016/S0049-3848(17)30066-X. PMID 28262233.
- ↑ Gómez-Puerta JA, Cervera R (2014). "Diagnosis and classification of the antiphospholipid syndrome". J Autoimmun. 48-49: 20–5. doi:10.1016/j.jaut.2014.01.006. PMID 24461539.
- ↑ Lockshin MD (2008). "Update on antiphospholipid syndrome". Bull NYU Hosp Jt Dis. 66 (3): 195–7. PMID 18937631.
- ↑ Gómez-Puerta, Jose A.; Cervera, Ricard (2014). "Diagnosis and classification of the antiphospholipid syndrome". Journal of Autoimmunity. 48-49: 20–25. doi:10.1016/j.jaut.2014.01.006. ISSN 0896-8411.